Zepbound vs. Wegovy: Which Obesity Treatment Might Be Right for You?

While both can be effective, they’re not the same. Here’s how Zepbound and Wegovy compare and how to decide which one might be right for you.
How Zepbound and Wegovy Work
Both medications are lab-made versions of certain hormones your body naturally produces that help control appetite and fullness. They contain different ingredients and work in similar but slightly different ways.
Who Can Use Wegovy and Zepbound?
There are differences in who can use these medications, says Thomas So, PharmD, a clinical pharmacist and senior manager of Consumer Drug Information Group at First Databank. Wegovy is approved for a broader age range, including some teens, while Zepbound is currently approved only for adults.
- Adults and children age 12 and older with obesity (a body mass index, or BMI, of 30 or higher)
- Adults and children age 12 and older who are overweight (a BMI of 27 or higher) and have at least one weight-related condition, such as high blood pressure, high cholesterol or triglycerides, or type 2 diabetes
- Adults with obesity
- Adults who are overweight and have at least one weight-related condition
Dosage
Weight Loss
Other Benefits
Beyond weight loss, both medications offer additional health benefits, says Dr. Kumar. They’re tools that can improve your overall health, not just help you see a lower number on the scale, she says.
Both Wegovy and Zepbound can improve blood sugar control by helping the body make more insulin and less sugar, says So. They can also support better blood pressure and cholesterol levels, often as a result of weight loss, he says. Plus, both medications may help with health issues related to being overweight or having obesity, such as joint pain, sleep apnea, and fatigue, says Connor.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Bloating
- Indigestion
- Stomach pain
- Burping
These side effects usually occur when you first start the medication or increase the dose, but tend to improve as your body adjusts, says Connor. Eating smaller meals, avoiding greasy foods, and staying hydrated can help manage them, she says. “In some cases, we slow down the dose increase to help patients tolerate the medication better,” says Kumar.
- Inflammation of the pancreas (pancreatitis)
- Gallbladder problems
- Kidney issues
- Mood changes
- A personal or family history of medullary thyroid cancer
- Multiple endocrine neoplasia syndrome type 2
- A known allergy to either medication or any of its ingredients
Cost
“Many plans still do not cover anti-obesity medications, such as Zepbound and Wegovy, even though strong evidence shows these treatments can improve long-term health outcomes and reduce future costs related to diabetes and heart disease,” says Kumar.
Even with insurance, coverage varies widely from plan to plan, says So. Differences can include which medication is covered, prior authorization requirements, copays, and deductibles. Some insurance plans have started covering Wegovy more widely, particularly after it gained FDA approval to reduce cardiovascular risk in 2024, says Connor.
Things to Consider Before Choosing
Choosing between Wegovy and Zepbound comes down to finding the option that fits your health goals, lifestyle, and what feels right for you. Here are a few things to consider as you discuss these with your doctor.
Your Weight Loss Goals
If the goal is significant weight loss, say around 20 percent or more of body weight, Zepbound might be the stronger choice, says So. “For moderate weight loss of about 10 percent to 15 percent, Wegovy may be enough,” he says.
Your Overall Health
Additional health conditions you’re managing can help guide your choice. For example, if you have heart disease, Wegovy’s cardiovascular benefits may make it a better fit. If you live with obstructive sleep apnea, Zepbound could offer an added advantage, says So.
Tolerance
Kumar suggests thinking through how well you tolerate medications. Some people find Wegovy’s slower dose increase easier on their stomach, while others do fine with Zepbound’s faster ramp-up.
Coverage and Cost
Check what your insurance covers and whether you’d need prior authorization for either medication. If you’re paying out of pocket, compare the savings programs and direct-to-consumer prices from both manufacturers.
Long-Term Success
The best and most sustainable long-term outcomes occur when these medications are combined with lifestyle changes, such as healthy eating, physical activity, adequate sleep, stress management, and ongoing follow-up, says So.
It also helps to talk openly with your healthcare provider about your goals, challenges, and concerns. Consider connecting with others who’ve used these medications or read discussions in trusted forums or support groups. Getting different perspectives can help you feel more informed and confident about which option might fit you best.
The Takeaway
- Wegovy and Zepbound are both FDA-approved injectable weight loss medications that work in similar but slightly different ways, though clinical trials show Zepbound may lead to more weight loss than Wegovy.
- Choosing between Wegovy and Zepbound depends on several factors. Wegovy offers heart health benefits for people with cardiovascular disease, while Zepbound is approved to treat obstructive sleep apnea in people with obesity.
- Side effects for both medications are mostly stomach-related and usually improve over time. If you experience severe abdominal pain, vomiting, or mood changes, contact your healthcare provider right away.
- These medications work best when paired with sustainable lifestyle habits like balanced eating, regular activity, good sleep, and stress management, along with ongoing support from a healthcare provider.
Resources We Trust
- Cleveland Clinic: The New Anti-Obesity Drugs: What You Should Know
- Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss
- Harvard Health: Questions and Answers About the New Anti-Obesity Medications
- Yale Medicine: Why Your Cardiologist May Prescribe Semaglutide (Wegovy)
- NewYork-Presbyterian: Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial
- Wegovy™ (semaglutide 2.4 mg), the First and Only Once-Weekly GLP-1 Therapy for Weight Management, Approved in the US. Novo Nordisk. June 4, 2021.
- FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
- Astrup A. Reflections on the Discovery GLP-1 as a Satiety Hormone: Implications for Obesity Therapy and Future Directions. European Journal of Clinical Nutrition. June 18, 2024.
- Wharton S et al. Two-Year Effect of Semaglutide 2.4 mg on Control of Eating in Adults With Overweight/Obesity: STEP 5. Obesity. January 18, 2023.
- Dutta P et al. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus. May 1, 2023.
- WEGOVY – Semaglutide Injection, Solution. DailyMed. August 1, 2025.
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight. U.S. Food and Drug Administration. March 8, 2024.
- FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’. U.S. Food and Drug Administration. August 15, 2025.
- ZEPBOUND – Tirzepatide Injection, Solution. DailyMed. July 7, 2025.
- FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. December 20, 2024.
- ZEPBOUND- tirzepatide injection, solution. DailyMed. July 7, 2025.
- WEGOVY- Semaglutide Injection, Solution. DailyMed. August 1, 2025.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. New England Journal of Medicine. February 10, 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. June 4, 2022.
- Aronne LJ et al. Tirzepatide as Compared With Semaglutide for the Treatment of Obesity. New England Journal of Medicine. May 11, 2025.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. New England Journal of Medicine. November 11, 2023.
- Ituarte BE et al. Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists. Journal of Drugs in Dermatology. August 19, 2024.
- Wang W et al. Association of Semaglutide With Risk of Suicidal Ideation in a Real-World Cohort. Nature Medicine. January 5, 2024.
- Sharma A et al. Semaglutide and the Risk of Diabetic Retinopathy-Current Perspective. Eye. August 9, 2021.
- How Much Should I Expect to Pay for Zepbound® (tirzepatide)? Lilly.
- What Is the List Price for Wegovy® and Will It Impact Me? NovoCare.
- Zepbound. LillyDirect.
- NovoCare Pharmacy. NovoCare.
- Quarenghi M et al. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of Clinical Medicine. May 28, 2025.

Sean Hashmi, MD
Medical Reviewer
Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.
Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.

Maggie Aime, MSN, RN
Author
Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content. Her extensive nursing background spans specialties like oncology, cardiology, and pediatrics. She has also worked in case management, revenue management, medical coding, and as a utilization review nurse consultant. She leverages her unique insights to help individuals navigate the U.S. healthcare system and avoid financial pitfalls.
Maggie applies her extensive clinical expertise to create empowering education for readers at all stages. She is passionate about illuminating issues from disease prevention to health and wellness to medical personal finance. Her work can be found in GoodRx Health, Next Avenue, HealthNews, Insider, Nursing CE Central, Nurse Blake, AllNurses, and BioHackers Lab.
An active member of several professional nursing and journalism associations, Maggie founded The Write RN to fulfill her calling to teach.
When she's not crafting the next great article, you can find Maggie volunteering, reading, playing the piano, or savoring sunrise views at the beach.